Pancreatic cancer is a biologically aggressive tumour that can spread early and is often diagnosed at advanced stages. Even so, specialists agree that this is a time of major progress, which World Pancreatic Cancer Day offers an opportunity to highlight, together with the importance of being able to refer patients to centres specialising in the disease. The combination of new targeted therapies such as RAS inhibitors, clinical trials available at different stages of the disease and advanced surgical techniques means that alternatives can now be offered even for very complex tumours.
RAS inhibitors: a new revolution in treatment
The RAS signalling pathway is altered in the vast majority of pancreatic cancers and is key to tumour growth. “For decades it has been one of the great challenges of cancer research. The new RAS inhibitors are showing very promising results and represent one of the therapeutic revolutions of recent years for this disease,” says Dr Teresa Macarulla, Head of the Medical Oncology Department at Hospital Clínic de Barcelona and head of the Translational Oncology of Upper Gastrointestinal Cancer group at IDIBAPS.
The 4CB is currently recruiting patients for the RASolute 304 trial, which is evaluating the RAS inhibitor daraxonrasib as adjuvant treatment, that is, after surgery, with the aim of reducing the risk of relapse. “Until now we had encouraging data for this drug as second-line treatment in metastatic disease, where we saw survival double in these patients, in the trial presented at the ASCO congress this past June. Now its efficacy must also be evaluated in earlier stages of the disease, and at Hospital Clínic we already have the trial up and running to do so.”
This trial adds to the growing clinical research activity at the 4CB. “In the coming years, new targeted therapies, precision medicine and advances in biomarkers will make it possible to better select treatments for each patient,” the oncologist adds.
From Mallorca to Hospital Clínic: the value of a second assessment
Magdalena came from Mallorca through the CSUR referral pathway to receive care for her pancreatic tumour, which involved the veins. Despite a good response to neoadjuvant treatment before surgery, an operation was not possible at her local hospital. After her case was reviewed by the multidisciplinary committee, the team was able to offer her a surgical option. Following the operation, she agreed to take part in the RASolute 304 clinical trial, as her profile met the inclusion criteria and the team considered it the best therapeutic option for her.
“An initially inoperable tumour does not necessarily mean it can never be operated on. A second opinion does not mean the previous treatment was wrong; it can open up new opportunities and give the patient and their family reassurance,” explains Dr Elizabeth Pando, surgeon in the Hepatobiliopancreatic Surgery and Transplant Unit at Hospital Clínic de Barcelona.
Through the Spanish Ministry of Health website, the family learned that it was possible to request an assessment at another centre through the Health Cohesion Fund (Fondo de Cohesión Sanitaria), a tool they believe should be better known. “We experienced it as a great opportunity after a year marked by uncertainty. Knowing that surgery was a real possibility gave us hope and allowed us to look to the future from a different perspective. To access it, you need a medical referral with the corresponding report. The process is relatively quick and, once the referral is accepted, the first appointment usually comes within about a month,” they explain.
Magdalena and her family wish to give special recognition to the medical oncology and surgical teams, led by Dr Macarulla and Dr Pando respectively, and to send a message of hope to anyone going through a similar experience. “We want to encourage everyone in a similar situation not to give up. Getting informed, asking for a second assessment and exploring all the available options can make a big difference. We have also learned how important it is to have an involved, well-informed companion. Understanding medical information, being able to ask questions and helping with decision-making is often essential support throughout the whole process.”
A reference centre for the most complex tumours
Hospital Clínic is one of three centres in Spain accredited as a CSUR for the surgical treatment of borderline resectable pancreatic cancer, including locally advanced tumours. This accreditation allows patients from other Spanish regions to access specialist assessment and highly complex treatments, such as venous and arterial vascular resections and reconstructions, or vascular bypasses in selected patients.
This experience is reflected in clinical activity. According to the latest data, by mid-October 2026 Hospital Clínic had already performed 50 pancreatic resections, the same number as in the whole of 2025. Of these cases, fourteen patients had borderline resectable or locally advanced tumours; twelve of them required venous resection and two, arterial resection. In addition, the Pancreatic Cancer Multidisciplinary Committee assessed 167 cases between March and October.
“It’s not just about performing complex operations, but about knowing which treatment to offer each patient, when, and how to combine it with the other available options,” says Dr Pando.
The patient at the centre of everything
Beyond treatments, the specialists emphasise how care is organised. The successful model will be one that truly brings together all professionals around the patient: oncology, surgery, nursing, radiology, endoscopy, nutrition, rehabilitation, psycho-oncology and palliative care. In this model, the specialist oncology nurse also plays a prominent role as the patient’s point of reference and coordinator, becoming central to ensuring that the care pathway runs as planned and that the patient receives the best care.
“Patients are not only looking for the best treatment: they need to feel safe, trust their team and know they will be supported throughout the process. Technical excellence must always go hand in hand with humane, compassionate care,” concludes Dr Pando.
